Trial Profile

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Adenocarcinoma; Alveolar soft part sarcoma; Chondrosarcoma; Chordoma; CNS cancer; Extranodal NK-T-cell lymphoma; Germ cell cancer; Haemangiosarcoma; Lymphoma; Myxoid liposarcoma; Neuroendocrine tumours; Ovarian cancer; Rhabdoid tumour; Sarcoma; Soft tissue sarcoma; Thyroid cancer
Focus Therapeutic Use
Acronyms AcSe

Most Recent Events

19 Jan 2024 Status changed from active, no longer recruiting to completed.
07 Jul 2023 Results (n=98) assessing the activity of pembrolizumab in rare and ultra-rare sarcomas published in the Lancet Oncology
06 Feb 2023 Planned End Date changed from 1 Dec 2023 to 26 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com